K
Kai Chu
Researcher at Centers for Disease Control and Prevention
Publications - 49
Citations - 2404
Kai Chu is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Immunogenicity & Vaccination. The author has an hindex of 16, co-authored 35 publications receiving 1425 citations.
Papers
More filters
Journal ArticleDOI
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Yanjun Zhang,Gang Zeng,Hongxing Pan,Changgui Li,Yaling Hu,Kai Chu,Weixiao Han,Zhen Chen,Rong Tang,Weidong Yin,Xin Chen,Yuansheng Hu,Xiao-Yong Liu,Cong-Bing Jiang,Jingxin Li,Minnan Yang,Yan Song,Xiangxi Wang,Qiang Gao,Fengcai Zhu +19 more
TL;DR: The primary safety endpoint was adverse reactions within 28 days after injection in all participants who were given at least one dose of study drug (safety population).
Journal ArticleDOI
Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Fengcai Zhu,Fengcai Zhu,Fan-Yue Meng,Jingxin Li,Jingxin Li,Xiu-Ling Li,Qunying Mao,Hong Tao,Yun-Tao Zhang,Xin Yao,Kai Chu,Qing-Hua Chen,Yuemei Hu,Xing Wu,Pei Liu,Lin-Yang Zhu,Fan Gao,Hui Jin,Yi-Juan Chen,Yu-Ying Dong,Yong-Chun Liang,Nianmin Shi,Heng-Ming Ge,Lin Liu,Sheng-Gen Chen,Xing Ai,Zhen-Yu Zhang,Yu-Guo Ji,Fengji Luo,Xiao-Qin Chen,Ya Zhang,Li-Wen Zhu,Zhenglun Liang,Xin-Liang Shen +33 more
TL;DR: Evaluating the efficacy, safety, immunogenicity, antibody persistence, and immunological correlates of an inactivated alum-adjuvant EV71 vaccine in healthy children from four centres in China found it provides high efficacy, satisfactory safety, and sustained Immunogenicity.
Journal ArticleDOI
Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial
Fengcai Zhu,Li-Hua Hou,Jingxin Li,Shipo Wu,Pei Liu,Gui-Rong Zhang,Yuemei Hu,Fan-Yue Meng,Junjie Xu,Rong Tang,Jie Zhang,Wen-Juan Wang,Lei Duan,Kai Chu,Qi Liang,Jialei Hu,Li Luo,Tao Zhu,Junzhi Wang,Wei Chen +19 more
TL;DR: The findings show that the high-dose vaccine is safe and robustly immunogenic and could mount glycoprotein-specific humoral and T-cell response against Ebola virus in 14 days.
Journal ArticleDOI
Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial
You-Lin Qiao,Ting Wu,Rong-Cheng Li,Yuemei Hu,Lihui Wei,Changgui Li,Wen Chen,Shoujie Huang,Fang-Hui Zhao,Mingqiang Li,Qin-Jing Pan,Xun Zhang,Qing Li,Ying Hong,Chao Zhao,Wen-hua Zhang,Yanping Li,Kai Chu,Mei Li,Yun-Fei Jiang,Juan Li,Hui Zhao,Zhijie Lin,Xuelian Cui,Wen-Yu Liu,Caihong Li,Dong-Ping Guo,Li-Dong Ke,Xin Wu,Jie Tang,Guo-Qi Gao,Ba-Yi Li,Bin Zhao,Fengxian Zheng,Cui-Hong Dai,Meng Guo,Jun Zhao,Yingying Su,Junzhi Wang,Fengcai Zhu,Shaowei Li,Huirong Pan,Yimin Li,Jun Zhang,Ningshao Xia +44 more
TL;DR: The Escherichia coli-produced HPV- 16/18 vaccine is well tolerated and highly efficacious against HPV-16/18 associated high-grade genital lesions and persistent infection in women.
Journal ArticleDOI
Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial
Fengcai Zhu,Zhenglun Liang,Xiu-Ling Li,Heng-Ming Ge,Fan-Yue Meng,Qunying Mao,Yun-Tao Zhang,Yuemei Hu,Zhen-Yu Zhang,Jingxin Li,Fan Gao,Qing-Hua Chen,Qi-Yan Zhu,Kai Chu,Xing Wu,Xin Yao,Hui-Jie Guo,Xiao-Qin Chen,Pei Liu,Yu-Ying Dong,Feng-Xiang Li,Xin-Liang Shen,Junzhi Wang +22 more
TL;DR: Taking immunogenicity, safety, and production capacity into account, the 320 U alum-adjuvant formulation of the EV71 vaccine is probably the best possible formulation for phase 3 trials.